Carl Morrow, Postdoctoral Researcher

DNA Damage and Repair
01865 222365
Main Researcher: 

Research Summary

Carl’s research is funded by Cancer Research UK and focuses on how the Bloom syndrome complex maintains genome stability and prevents cancer formation.


I completed my PhD in 2012 at the University of Queensland, Australia, in the laboratory of Associate Professor James Fraser, where I worked on the fungus Cryptococcus neoformans, an AIDS-associated opportunistic pathogen that causes meningoencephalitis. I investigated aspects of purine metabolism that could be targeted for antifungal therapy, as well as mechanisms of rapid microevolution that occurred in the fungus during long-term infection of a human host.

In 2013 I moved to the University of Oxford to the laboratory of Professor Matthew Whitby, where I studied mechanisms of replication fork restart via homologous recombination in the yeast Schizosaccharomyces pombe. In particular, I uncovered a new mechanism of genome instability encountered when a restarting replication fork encounters a normal terminating fork, which was mediated by the structure specific nuclease Mus81.

In 2016 I moved to the laboratory of Dr Andrew Blackford, where I work on genome stability and DNA damage repair, in particular the Bloom syndrome tumour suppressor complex. The complex performs myriad roles in protecting and repairing the genome during DNA replication and repair and is a particularly potent suppressor of cancer formation in all cell types. I am utilising cutting-edge proteomics approaches to uncover and investigate key protein-protein interactions of the complex that may potentially mediate its role in maintaining and repairing the integrity of the genome and in turn prevent the development of cancer.

About Us
We aim to enhance clinical and basic cancer research in Oxford with the ultimate goal of increasing cancer cure rates.
In Oxford, we have a great wealth of broad-ranging expertise and a powerful network of cancer researchers.
Study With Us
Our graduate training programmes for both scientists and clinicians are internationally recognised.